POTELIGEO® (mogamulizumab-kpkc) is a humanized monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including cutaneous T-cell lymphomas (CTCL), such as mycosis fungoides (MF) and Sézary syndrome (SS). By binding to CCR4 on malignant T-Cells, POTELIGEO® elicits an antitumor activity mediated by antibody-dependent cellular cytotoxicity (ADCC) leading to the death of malignant T-Cell.
POTELIGEO® was produced using Kyowa Kirin's proprietary POTELLIGENT® platform.
This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information: